Form 4: ALUMIS Director Patrick Machado Reports Significant Share and Option Holdings Post-ACELYRIN Merger

ALUMIS INC. Director Patrick Machado has reported the acquisition of common stock and conversion of multiple stock options into ALUMIS shares following the completion of the merger with ACELYRIN, Inc.

Summary

• Patrick Machado, a Director of ALUMIS INC. (ALMS), filed a Form 4 detailing changes in his beneficial ownership of securities.
• The reported transactions occurred on May 21, 2025, coinciding with the effective time of the merger between ALUMIS INC. and ACELYRIN, Inc.
• As a result of the merger, Patrick Machado acquired 7,064 shares of ALUMIS Common Stock indirectly through the Patrick Machado Revocable Trust.
• Additionally, five employee stock options to acquire ACELYRIN common stock were converted into options to purchase ALUMIS Class A Common Stock.
• The converted options include: 44,364 shares at an exercise price of $9.26, 11,189 shares at $37.39, 41,499 shares at $12.21, 13,804 shares at $12.21, and 19,528 shares at $1.60.
• All converted stock options are fully vested and exercisable.
• The conversion was based on an Exchange Ratio of 0.4814 shares of ALUMIS voting common stock for each share of ACELYRIN common stock.
• The exercise prices of the converted options were adjusted by dividing the original ACELYRIN exercise price by the Exchange Ratio.

Sentiment

Score: 7

Explanation: The sentiment is positive as it confirms the successful completion of a significant corporate event (merger) and details the resulting, expected changes in insider ownership, which aligns insider interests with the combined entity's performance.

Positives

• The completion of the merger between ALUMIS INC. and ACELYRIN, Inc. signifies strategic growth and potential synergies for the combined entity.
• The director's increased beneficial ownership aligns his interests with those of the shareholders of the newly combined company.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance beyond the completion of the merger and the resulting changes in beneficial ownership.

Industry Context

This filing reflects the successful completion of a merger in the biotechnology or pharmaceutical sector, indicating consolidation and strategic expansion for ALUMIS INC. by integrating ACELYRIN, Inc. This is a common strategy for growth and pipeline diversification in the industry.

Stakeholder Impact

• Shareholders of ACELYRIN, Inc. have had their shares converted into ALUMIS INC. common stock, impacting their ownership structure.
• Shareholders of ALUMIS INC. now own a larger, combined entity, potentially benefiting from the strategic integration of ACELYRIN's assets and pipeline.
• Patrick Machado, as a director, has increased his beneficial ownership in ALUMIS, aligning his financial interests with the company's performance post-merger.

Key Dates

Keywords

ALUMIS INC., ALMS, ACELYRIN, Merger, Form 4, Insider Trading, Stock Option, Beneficial Ownership, Corporate Governance, Biotechnology